CRMD Phase3 Neutrolin

When:
July 1, 2018 @ 8:00 am – July 15, 2018 @ 4:30 pm
2018-07-01T08:00:00-04:00
2018-07-15T16:30:00-04:00

CRMD, CorMedix, Inc., has an upcoming Phase3 data due 2H 2018, LOCK-IT 100 study for Neutrolin® with interim analysis due (most likely) early July 2018.
https://www.marketwatch.com/story/cormedix-inc-reports-progress-on-lock–it-100-data-review-and-appoints-paul-chew-as-consultant-advisor-cmo-2018-05-29

Last Offering the company did seems to be May 2017. No open effect form found.

CRMD SEC filings: http://www.cormedix.com/investors/sec-filings/